Abstract
The ESS-1 study was designed to evaluate the long-term effects of the angiotensin- converting enzyme inhibitor (ACEI) enalapril (10 mg per day) on cardiopulmonary system of patients with systemic sclerosis (SSc). Exercise testing is used not only for estimation of coronary reserve but also physical capacity—the major determinant of quality of life. In each patient included to the ESS-1 study we performed ECG exercise test on treadmill (5 times at intervals of 3 months).
The first follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). The exercise duration in the placebo group was 683±295sec and in enalapril group 768±173sec. After 3 months of study there were no significant differences in both groups (758±271 sec and 720±191 sec respectively). The analysis of ST segment deviation did not provide any significant changes after 3 months of treatment. We conclude that 3 months enalapril treatment did not improve exercise tolerance in patients with systemic sclerosis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
LeRoy E.C. Systemic sclerosis. In: Wyngaarden JB, Smith LH Jr eds. Cecil Textbook of Medicine. Philadelphia: W.B. Saunders. 2018–33 (1988).
Sudduth CD, Strange C, Cook WR, Miller KS, Baumann M, Collap NA, Silver RM. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 95: 413–8 (1993).
Bulpitt KJ, Clements PJ, Lachenbruch PA et al: Early undifferentiated connective tissue Disease: III. Outcome and prognostic indicators in early scleroderma. Ann Int Med. 118: 602–9 (1993).
Kawaguchi H, Kitabatake A. Altered signal transduction system in hypertrophied myocardium: angiotensin stimulates collagen synthesis in hypertrophied hearts. J of Card Failure. 2(4 suppl): S13–9 (1996).
Kligfield P, Okin PM, Ameisen O, Borer JS: Evaluation of coronary artery disease by an improved method of exercise electrocardiography: the ST segment/heart rate slope. Am Heart J. 112: 589–598 (1986).
Blom-Bulow B, Jonson B, Bauer K. Factors limiting exercise performance in progressive systemic sclerosis. Semin Arthritis Rheum. 13: 174–81 (1983)
Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 75: 65–74 (1983).
Cohn JN: Drug Therapy: The Management of Chronic Heart Failure [Review Article] The New Eng J of Med. 335: 490–498 (1996).
Kahan A, Nitenberg A, Foult JM et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum. 28: 637–646 (1985).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Biłan, A. et al. (1999). Enalapril (10 Mg/Day) in Systemic Sclerosis. In: Mallia, C., Uitto, J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4857-7_41
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4857-7_41
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7203-5
Online ISBN: 978-1-4615-4857-7
eBook Packages: Springer Book Archive